Biogen Inc. (NASDAQ:BIIB) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Biogen Inc. (NASDAQ:BIIB) have received a consensus recommendation of “Moderate Buy” from the twenty-nine brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation, fourteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $215.6154.

Several equities research analysts recently weighed in on BIIB shares. Stifel Nicolaus lifted their price target on Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Freedom Capital upgraded Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Oppenheimer lifted their price target on Biogen from $275.00 to $300.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. The Goldman Sachs Group lifted their price target on Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Finally, Mizuho lifted their price target on Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th.

Institutional Investors Weigh In On Biogen

Hedge funds have recently made changes to their positions in the company. Reflection Asset Management bought a new stake in shares of Biogen during the fourth quarter valued at approximately $25,000. WPG Advisers LLC boosted its holdings in Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 117 shares in the last quarter. First Horizon Corp bought a new stake in Biogen in the fourth quarter worth $30,000. Root Financial Partners LLC boosted its holdings in Biogen by 198.4% in the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 123 shares in the last quarter. Finally, MV Capital Management Inc. bought a new stake in Biogen in the fourth quarter worth $34,000. 87.93% of the stock is currently owned by institutional investors.

Biogen Price Performance

BIIB opened at $190.56 on Wednesday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. Biogen has a 52-week low of $121.05 and a 52-week high of $205.97. The stock has a market capitalization of $28.13 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 1.69 and a beta of 0.19. The stock’s 50 day moving average price is $185.40 and its 200-day moving average price is $180.14.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same period in the previous year, the firm earned $3.02 earnings per share. The business’s revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities research analysts predict that Biogen will post 14.18 EPS for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.